Editas Medicine Inc

EDIT

1.820USD

+0.155+9.31%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Editas Medicine Inc's Score

Industry at a Glance

Industry Ranking

121 / 392

Overall Ranking

257 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Editas Medicine Inc Highlights

StrengthsRisks

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 63.93% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 32.31M.

Overvalued

The company’s latest PE is -0.78, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 46.01M shares, increasing 0.01% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 31.67K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.28.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

5.214

Target Price

+213.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Editas Medicine Inc is 7.25, ranking 135 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 7.54M, representing a year-over-year increase of 12265.57%, while its net profit experienced a year-over-year increase of 59.58%.

Score

Industry at a Glance

Previous score

7.25

Change

0



Financials

7.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.12

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Editas Medicine Inc is 7.75, ranking 83 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.78, which is -58.42% below the recent high of -0.32 and -607.83% above the recent low of -5.49.

Score

Industry at a Glance

Previous score

7.75

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 121/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Editas Medicine Inc is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 13.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Editas Medicine Inc is 5.55, ranking 310 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.28 and the support level at 1.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.26

Change

0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Editas Medicine Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 66.91%, representing a quarter-over-quarter decrease of 8.52%. The largest institutional shareholder is The Vanguard, holding a total of 8.21M shares, representing 8.41% of shares outstanding, with 5.72% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

6.97M

-2.71%

BlackRock Institutional Trust Company, N.A.

6.81M

+10.31%

Two Sigma Investments, LP

2.79M

+45.12%

Geode Capital Management, L.L.C.

2.04M

+3.86%

Nuveen LLC

1.98M

+112.06%

State Street Investment Management (US)

1.93M

+4.23%

Renaissance Technologies LLC

Star Investors

1.28M

+43.79%

UBS Asset Management Switzerland AG

1.17M

--

SELECTRA Management Company S.A.

1.11M

+0.90%

BofA Global Research (US)

1.02M

-5.14%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Editas Medicine Inc is 3.62, ranking 132 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Editas Medicine Inc

EDIT

6.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment